During the past decade, Hauttumorcentrum Charité (HTCC) conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hauttumorcentrum Charité (HTCC)" are "Actinic Keratosis" (2 trials) and "Nodular Basal Cell Carcinoma" (1 trials). Many other conditions were trialed in "Hauttumorcentrum Charité (HTCC)" in a lesser frequency.

Most popular intervention types in "Hauttumorcentrum Charité (HTCC)" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "0.06% Resiquimod Gel - A" (1 trials), "0.06% Resiquimod Gel - B" (1 trials), "0.06% Resiquimod Gel - C" (1 trials), "Resiquimod 0.01%" (1 trials) and "Resiquimod 0.03%" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hauttumorcentrum Charité (HTCC)" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Hauttumorcentrum Charité (HTCC)". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Hauttumorcentrum Charité (HTCC), undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hauttumorcentrum Charité (HTCC), 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".